miRNA in Septic Acute Kidney Injury
Specific miRNA Associated With Endothelial Dysfunction and Mitochondrial Damage in Patients With Septic Acute Kidney Injury
University Hospital Ostrava
220 participants
May 2, 2024
OBSERVATIONAL
Conditions
Summary
Acute kidney injury is a common and serious complication of sepsis and septic shock, which may be associated with a worse outcome of the patient's condition. The exact pathophysiological mechanism of septic acute kidney injury remains a challenge. One of the possible causes appears to be endothelial dysfunction and mitochondrial damage of renal tubular cells. The aim of this study is to identify specific microRNAs associated with these pathophysiological events in sepsis and septic acute kidney injury. And to establish a new potential diagnostic or therapeutic target for the prevention or treatment of septic acute kidney injury.
Eligibility
Inclusion Criteria7
- The study group of patients with sepsis with or without acute kidney injury
- age \> 18 years
- newly diagnosed sepsis or septic shock with or without acute kidney injury
- Healthy volunteers
- no evidence of infection on clinical or laboratory examination
- age \> 18 years
- signed informed consent
Exclusion Criteria7
- The study group of patients with sepsis with or without acute kidney injury
- age \< 18 years
- chronic kidney disease at stage 4 or 5 according to KDIGO recommendations (KDIGO) for chronic kidney disease 2024
- patients on chronic dialysis treatment, or after renal transplantation
- Healthy volunteers
- acute or chronic infection
- renal disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Standard laboratory biochemical methods will be used to determine sepsis diagnosis accord-ing to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
Standard laboratory biochemical methods will be used to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to Guidelines Kidney Disease Improving Global Outcomes (KDIGO) 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
Laboratory examination will be performed to determine miRNA and biochemical parameters.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06498336